Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PRE and 80,000+ other tickers.
See exactly how PRE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PRE and 80,000+ other tickers.
As an investment holding company, Prenetics Global Limited specializes in providing diagnostic and genetic testing services. Its comprehensive product line features CircleDNA, a consumer-oriented genetic analysis solution, and the Circle HealthPod, an advanced health monitoring device. The Circle HealthPod facilitates rapid COVID-19 detection through nucleic acid amplification technology, suitable for both professional point-of-care and personal at-home use. Additionally, the company offers ColoClear, a non-invasive FIT-DNA screening test for colorectal cancer, and Circle SnapShot, a readily…
Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer health company and parent of the AI-native direct-to-consumer wellness brand IM8, co-founded by David Beckham, today announced that Danny Yeung, Chief Executive Officer, and Brian Rosin, Chief Financial Officer, completed open market purchases of the Company's ordinary shares during the period between August 20 and August 25, 2026, within the Company's open trading window following the release of second quarter 2026 financial results. The two executives acquired $1.0 million of shares.
Prenetics Global Limited has achieved explosive growth, reaching 140,000 subscriptions in 20 months, driven by its IM8 supplement and AI-powered marketing. One of the keys to this growth is its marketing mastery, using A/B and multivariate testing to quickly identify the most effective advertising messages. A unique deal with General Catalyst enables PRE to finance up to 70% of customer acquisition costs without equity dilution or debt, amplifying marketing leverage.
Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript
— Lily is IM8's first Global Ambassador from film and television, extending a roster built in elite sport into global entertainment and culture — Lily brings a following of more than 33 million across social platforms and an engagement rate of approximately 5.9%, several times the benchmark for accounts of comparable scale — Partnership lands as Prenetics raises FY 2026 revenue guidance to $220+ million; Initiates FY 2027 revenue guidance of $400+ million — Joins an equity-aligned roster of David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, Jay Shetty and Inter Miami CF NEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced a multi-year global partnership with two-time Golden Globe-nominated actress and producer Lily Collins, star and executive producer of Netflix's Emily in Paris. Collins becomes a Global Ambassador of IM8 and a shareholder in Prenetics, demonstrating her long-term conviction in the brand and the Company.
Prenetics Global NASDAQ: PRE reported second-quarter revenue of $46.5 million, up 29% sequentially and about 3.9 times from a year earlier, as its IM8 supplement business continued to add subscribers and scale marketing spending. The company raised its full-year revenue outlook and said July marked its first month of positive consolidated adjusted free cash flow, including funding provided under its General Catalyst facility.